Please login to the form below

Does your pre-launch strategy really drive behaviour change?

One of the most interesting parts of a pharmaceutical launch is delving into the minds of stakeholders to understand why they behave in the way that they do. Blue Latitude Health Insight Consultant, Dorrotya Okros, examines how we use these insights to understand customers decision making behaviour, in order to make smarter business decisions.

One of the most interesting parts of a pharmaceutical launch is delving into the minds of the stakeholders to understand why they behave in the way that they do.

Through embarking on this process, we can uncover the drivers that lead healthcare professionals to make decisions, along with the influences that shape patients’ information-seeking behaviour. We embark on a journey filled with twists and turns as we come closer to the truth and uncover why stakeholders think and feel a certain way.

In order to shape the market, pharmaceutical teams have to understand the current landscape. It’s important to guarantee the customer engagement plan is on target, ensuring that the right people are engaged, at the right time and in the right way. Insights sit at the heart of this, preventing brand teams from basing their strategy on assumptions rather than facts.

Insight comes from combining a deep understanding of customers with an understanding of the market. It is about aligning customers’ needs and the needs of the business to uncover brand opportunities. While traditional market research can help you identify the unmet needs of your audience, it will not tell you why that unmet need exists in the first place and, unlike insight, it will not offer possible solutions.

In this respect, insight goes beyond traditional market research. Achieving insight means truly listening to customers to understand why they make the decisions they make in the environments they operate in.

Challenging assumptions in rare disease

In 2018, we mapped the physician’s journey when diagnosing a patient with a rare progressive disease. Approximately, five in 100,000 people are diagnosed with this illness. Due to the scarcity of the disease, patients are often misdiagnosed with other ‘mimic’ diseases that present similar symptoms

Historically, there had been no disease modifying treatment available for these patients. However, a new therapy was entering the market and the progressive nature of the illness meant it was essential for patients to receive the treatments as early as possible.

The brand team assumed the physician was using a specific diagnostic scale designed to identify the rare disease and measure progression.

However, when we interviewed doctors, they said the test was complex and laborious to use – it did not meet their needs in the clinical setting. Instead, they were using a test designed for a far more common illness.

Armed with these insights, the brand team added a secondary endpoint which clearly indicated that physicians could use an altered version of the simpler test to make a faster diagnosis. Simultaneously, the team developed core relationships with both the rare disease patient groups and also with the groups associated with the mimic disease. This helped them reach a wider network of undiagnosed patients. Additionally, a disease awareness campaign to illustrate the importance of accurate diagnosis became an integral part of the launch strategy.

“If the team had not understood why the healthcare professionals were failing to use the scale, they could not have improved the method for diagnosing the rare disease”

The brand team would have also missed the opportunity to improve drug uptake and drive further awareness of the rare disease across the wide network of patient communities.

31st October 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health
Fishawack Health adds market access and commercial strategy consultancy Skysis as part of its bold growth plans
Fishawack Health, the global healthcare communications agency, announces the acquisition of Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.
Blue Latitude Health
Perspective: the patient edition
In this issue of Perspective magazine, we explore how the industry can place a greater emphasis on patient-centricity, and how pharmaceutical companies are working with patients across the product lifecycle to develop therapies that better serve their unmet needs.
Blue Latitude Health
The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the power of a strong patient community, while explaining how the charity is working with healthcare professionals to support patients, both physically and mentally.
Blue Latitude Health
Digital Nation: How Australia became a digital health pioneer
Australia has adopted digital strategies to transform its healthcare system. We sat down with Rachel de Sain, who shares where, and how she contributed to improving digital health products and services in Australia to advance their nation to becoming one of the world's leaders in digital health.
Blue Latitude Health
Rethinking Electronic Medical Records
EMR systems are far from perfect. Clinician and PhD candidate Dr. Pao takes us through his perspective on the system and how he aims to lead the way by solving the challenges when adopting this technology in a clinical setting.
Blue Latitude Health